The global NGS product market is projected to grow significantly from 2020 to 2035. In 2025, market revenue is estimated at USD 7,150 Million, accelerating as clinical genomics, personalized medicine, and research adoption intensify. By 2030, revenues are expected to surpass USD 15,600 Million, driven by expansion in oncology diagnostics, pharmaceuticals, and emerging markets. By 2035, industry size may reach approximately USD 29,400 Million, reflecting robust CAGR across all primary segments. This dynamic trajectory highlights the transformative potential of NGS in healthcare and life sciences worldwide.
Read More - https://bussinessinsights.com/research-report/global-next-generation-sequencing-(ngs)-product
Diagnostics dominate the application landscape for NGS products in 2025, propelled by the surging adoption of genetic testing, oncology sequencing panels, and infectious disease surveillance. Drug discovery also commands a significant portion, with pharmaceutical and biotech companies leveraging NGS for target identification and biomarker research. Biomarker discovery continues to expand as clinical research intensifies on personalized and stratified medicine. Other applications such as agriculture, animal research, and forensics, while smaller, are experiencing steady growth due to the broadening availability and scalability of NGS technologies.
Request Free Sample- https://bussinessinsights.com/request/consumers-goods/global-next-generation-sequencing-(ngs)-product
Who are the key players in Global Next Generation Sequencing (NGS) Product industry?
The top five key players in the Global NGS product industry are Illumina, Thermo Fisher Scientific, BGI Group, Agilent Technologies, and Roche. These companies dominate the market by constantly launching innovative sequencing technologies, expanding their global reach, and offering comprehensive product portfolios to meet the demands of diverse genomic research applications.
What is the Global Next Generation Sequencing (NGS) Product growth?
The Global NGS product market has experienced significant growth, driven by rising demand for precision medicine and diagnostics. For instance, Illumina reported a growth in sequencing consumables revenue in 2023, highlighting increased adoption in clinical diagnostics, cancer genomics, and research applications, spurring overall market expansion.
Which segment accounted for the largest Global Next Generation Sequencing (NGS) Product share?
The largest share in the NGS market comes from the oncology application segment. NGS is extensively used for cancer genome profiling, diagnosis, and personalized therapy. Rising cancer prevalence and the adoption of liquid biopsy tests using NGS platforms have propelled this segment's dominance in the global market.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com